Posts

Posted on

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021.

Jay Roberts, Chief Executive Officer of Vyant Bio, will discuss corporate, scientific, and operational updates in relation to the Company’s recent merger between the predecessor, Cancer Genetics, Inc., and StemoniX, Inc. Mr. Roberts will be joined on the call by Vyant Bio’s Chief Innovation Officer, Ping Yeh, and Chief Financial Officer, Andy LaFrence. Please also visit the Investors’ section of the Vyant Bio web site for details on how to participate.

Event:         Investor Webcast – Announcement of Vyant Bio
Date:           Tuesday, April 6, 2021
Time:           4:30pm ET
Webcast:    https://edge.media-server.com/mmc/p/sxogu3xt
Dial In:        (844) 954-2324 Conference ID: 9757240

A live and archived webcast of the conference call will also be available inside the Investors section of the Vyant Bio corporate website at www.vyantbio.com.

ABOUT VYANT BIO, INC.


Vyant Bio, Inc.
 (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients.

vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.

For more information, please visit or follow Vyant Bio at:

Internet:

www.vyantbio.com

LinkedIn: https://www.linkedin.com/company/vyant-bio

Twitter: @VyantBio

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contacts:

Jennifer K. Zimmons. Ph.D.
Investor Relations
Zimmons International Communications, Inc.
Email: [email protected]
Phone: +1.917.214.3514

Source: Vyant Bio, Inc.

 ###



Posted on

FCPT Announces Acquisition of an Individual Chili’s and a Dual-Tenant Starbucks / T-Mobile for $5.8 Million

FCPT Announces Acquisition of an Individual Chili’s and a Dual-Tenant Starbucks / T-Mobile for $5.8 Million

MILL VALLEY, Calif.–(BUSINESS WIRE)–
Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership of high-quality, net-leased restaurant properties (“FCPT” or the “Company”), is pleased to announce the acquisition of two properties for $5.8 million, an individual Chili’s and a dual-tenant property leased to Starbucks and T-Mobile. All three leases are with the brand’s corporate tenant under long-term, net leases. The properties are both newer builds and located in dense retail corridors in Massachusetts and New York. The transaction was priced at a capitalization rate consistent with previous FCPT transactions.

About FCPT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. Additional information about FCPT can be found on the website at www.fcpt.com.

Four Corners Property Trust:

Bill Lenehan, 415-965-8031

CEO

Gerry Morgan, 415-965-8032

CFO

KEYWORDS: United States North America Massachusetts California New York

INDUSTRY KEYWORDS: REIT Restaurant/Bar Retail Commercial Building & Real Estate Construction & Property

MEDIA:

Posted on

Heritage Cannabis Announces Strategic Re-financing with $7.0 Million Senior Secured Term Loan

Heritage Cannabis Announces Strategic Re-financing with $7.0 Million Senior Secured Term Loan

New strategic financing replaces existing loan agreement, extends maturity and removes international growth constraints

TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that it has entered into an 18 month non-revolving loan agreement (the “Loan Agreement”) with BJK Holdings Ltd. (“BJK”) in the amount of $7.0 million (the “Loan”). Pursuant to the Loan Agreement, BLK advanced the Company $7.0 million on April 1, 2021 (the “Closing Date”).

The Loan is payable in full upon maturity of the Loan, 18 months following the Closing Date, with monthly interest only payments made based on the outstanding balance of the Loan, calculated monthly, in arrears. Monthly interest will be calculated at the Royal Bank of Canada prime lending rate plus 1.25%. A one-time setup fee of $965,000 is due to BJK on the Closing Date. The Loan may be prepaid in full at any time without penalty.

A portion of the proceeds from the Loan was used to repay all of the Company’s credit facility obligations to Trichome Financial Corp. (“Trichome Credit Facility”) which was set to mature on January 30, 2022. The total payout to retire the Trichome Credit Facility was approximately $4.7 million and includes accrued interest, voluntary prepayment fees, and closing fees.

“With our positive long-term financial outlook, we are extremely pleased to be in a position to secure capital that increases our flexibility to grow our business internationally as a result of the improved terms over our prior loan arrangement and at the same time extends our re-payment date to October 2022 from January 2022,” commented Clint Sharples, CEO of Heritage. “In combination with our recent equity financing, we have strengthened our financial position and are poised for our product launches in the U.S. market. This new financing furthers our flexibility to execute our international strategy and allows for growth in a controlled but faster pace.”

“We have been following Heritage and their subsidiary Premium 5 for some time now and are excited to become their lending partner given that they are well on their way to establishing the Company as a leader in the cannabis extract and extract derivatives space,” commented David Thiessen of BJK. “We are confident in their ability to execute on their strategy and look forward to being a strong supporter and helping them as they expand their domestic presence internationally.”

Heritage will use the proceeds of the Loan to repay its existing facility and for general corporate purposes.

About Heritage Cannabis Holdings Corp.

Heritage is a cannabinoid company focused on the production and sale of medical and recreational hemp-based and cannabis-based products and services. In Canada, Heritage operates through its subsidiaries Voyage Cannabis Corp. and CannaCure Corporation, both regulated under the Cannabis Act Regulations. Working under these subsidiaries and the Purefarma, Pura Vida, Premium 5, RAD and feelgood. brands, Heritage focuses on extraction and the creation of derivative products for recreational consumers, as well as the formulation of cannabis based medical solutions. In the U.S., Heritage operates under Opticann Inc., a Colorado based oral and topical cannabinoid company with the rights to exclusively sell CBD and CBG products made with the patented VESIsorb® drug delivery system for optimized absorption and stability. As the parent company, Heritage is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“Clint Sharples”

Clint Sharples

CEO

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information contained herein may include, but is not limited to, assumptions related to cash flow and capital resources, and expectations related to the supply and manufacturing agreements, the intended expansion of the Company, and partnerships and Joint Venture Partnerships.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements.

An investment in securities of the Company is speculative and subject to several risks including, without limitation, the risks discussed under the heading “Risks and Uncertainties” in the Company’s annual management discussion and analysis for the year ended October 31, 2020 and dated February 26, 2021. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.

In connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice.

For more information contact:

Clint Sharples

Tel: 416-705-8529

[email protected]

or

Kelly Castledine

Tel: 647-660-2560

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Retail Specialty Agriculture Natural Resources

MEDIA:

Logo
Logo
Posted on

Everspin Announces Resignation of Chief Financial Officer

Everspin Announces Resignation of Chief Financial Officer

CHANDLER, Ariz.–(BUSINESS WIRE)–
Everspin Technologies, Inc. (NASDAQ: MRAM), the market leader in MRAM, today announced that Daniel Berenbaum has notified the company of his decision to resign as Chief Financial Officer to pursue another opportunity overseas. Mr. Berenbaum’s last day with the company is expected to be on April 16, 2021.

“We would like to thank Dan for his contributions to the company and wish him well in his future endeavors,” said Darin Billerbeck, Interim Chief Executive Officer of Everspin.

In connection with Mr. Berenbaum’s resignation, the company has appointed Aparna Oka to serve as the company’s principal financial officer and principal accounting officer on an interim basis, effective April 16, 2021, while the company conducts a search for its next Chief Financial Officer. Ms. Oka currently serves as Corporate Controller of Everspin.

About Everspin Technologies

Everspin Technologies, Inc. is the world’s leading provider of Magnetoresistive RAM (MRAM). Everspin MRAM delivers the industry’s most robust, highest performance non-volatile memory for Industrial IoT, Data Center, and other mission-critical applications where data persistence is paramount. Headquartered in Chandler, Arizona, Everspin provides commercially available MRAM solutions to a large and diverse customer base. For more information, visit www.everspin.com. NASDAQ: MRAM

Darin Billerbeck, Interim CEO

[email protected]

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Semiconductor Engineering Consumer Electronics Technology Manufacturing Hardware

MEDIA:

Posted on

Sensata Technologies Completes Acquisition of Xirgo Technologies

Sensata Technologies Completes Acquisition of Xirgo Technologies

SWINDON, England–(BUSINESS WIRE)–
Sensata Technologies (NYSE: ST), a leading industrial technology company and provider of sensor-rich solutions that create insight for customers, today announced that it has completed the previously announced acquisition of leading telematics and data insight provider, Xirgo® Technologies Intermediate Holdings, LLC (“Xirgo”) for $400 million.

Sensata completed the acquisition of 100% of the shares from private equity firm HKW and other shareholders following receipt of regulatory approval from all authorities required by the agreement. The acquisition includes approximately 160 sales, engineering and manufacturing employees in the United States and Lithuania including more than 75 engineers.

“This acquisition meaningfully advances Sensata’s Smart & Connected megatrend-focused growth initiative for transportation and logistics end-markets. We are excited to welcome our new Xirgo colleagues to Team Sensata as we work together to deliver a broader value proposition to address fleet managers’ needs and create new growth opportunities for our employees and our shareholders,” said Jeff Cote, Sensata Technologies CEO and President.

To learn more about how the acquisition expands Sensata’s Smart & Connected growth vector and strengthens its position as a data insight provider across transportation and logistics end-markets, read the previous signing announcement.

About Sensata Technologies

Sensata Technologies is a leading industrial technology company that develops sensors, sensor-based solutions, including controllers and software, and other mission-critical products to create valuable business insights for customers and end users. For more than 100 years, Sensata has provided a wide range of customized, sensor-rich solutions that address complex engineering requirements to help customers solve difficult challenges in the automotive, heavy vehicle & off-road, industrial and aerospace industries. With more than 19,000 employees and operations in 13 countries, Sensata’s solutions help to make products safer, cleaner and more efficient, more electrified, and more connected. For more information, please visit Sensata’s website at www.sensata.com.

About Xirgo® Technologies, LLC

Xirgo® Technologies, LLC is a leading provider of innovative, full-featured, application-specific wireless IoT communication devices. An expansive product line facilitates best-in-class solutions for numerous markets and verticals. With comprehensive in-house engineering capabilities in all key development disciplines, Xirgo consistently delivers compelling solutions to companies in search of ways to become more competitive, improve operational efficiencies, and unlock new revenue streams. In conjunction with our partners, Xirgo has provided world-class solutions in the realm of telematics, fleet management, heavy equipment, asset tracking, usage-based driving, high-risk vehicle finance, cold chain, and rental applications. For more information about Xirgo, visit the website: https://xirgo.com/

Investors:

Jacob Sayer

+1 (508) 236-1666

[email protected]

Media:

Alexia Taxiarchos

+1 (617) 259-8172

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Trucking Transport Logistics/Supply Chain Management

MEDIA:

Posted on

Diazyme Laboratories, Inc. Announces CE-IVD for its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test

SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) — Diazyme Laboratories, Inc. announced March 30th that it has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test. The Diazyme test is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay, which has been used to evaluate the adaptive immune response in vaccine studies1. Diazyme also announced plans to work with US FDA for EUA application.

“Unlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme’s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and health authorities a valuable tool to evaluate the level of effective antibodies generated after infection or vaccination, and to assess adaptive immunity in studies going forward. Diazyme serology tests meet real world expectations from healthcare professionals and have been independently evaluated in several published studies2–4,” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories, Inc.

About Diazyme

Diazyme Laboratories, Inc., a Life Science Affiliate of General Atomics, is located in Poway, California, USA. Diazyme uses its proprietary enzyme and immunoassay technologies to develop diagnostic test reagents run on automated chemistry analyzers and chemiluminescence instruments in user-friendly formats. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. Information regarding Diazyme’s technology and products can be found on its website at www.diazyme.com

For Further Information Contact:

Sales and Marketing

Emile Dergham
[email protected]

Regulatory/Operational

Abhijit Datta, Ph.D.
[email protected]

References

  1. E E. Walsh, M.D., R W. Frenck, Jr., M.D., A R. Falsey, M.D., et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates,
    New England Journal of Medicine, 2020; 383:2439-2450
    ,

    https://www.nejm.org/doi/full/10.1056/NEJMoa2027906
  2. R T. Suhandynata, M A. Hoffman, M J. Kelner,
    et al
    ., Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19, 
    The Journal of Applied Laboratory Medicine
    , Volume 5, Issue 5, September 2020, Pages 908–920, https://doi.org/10.1093/jalm/jfaa079
  3. R T. Suhandynata, M A. Hoffman, M J. Kelner,
    et al
    ., Multi-Platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19, 
    The Journal of Applied Laboratory Medicine
    , Volume 5, Issue 6, November 2020, Pages 1324–1336, https://doi.org/10.1093/jalm/jfaa139
  4. R T. Suhandynata, N J. Bevins, J T. Tran, et al., SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses, medRxiv, 2021.03.10.21253299; doi:

    https://doi.org/10.1101/2021.03.10.21253299

 



Posted on

AMONG THE FIRST: RENOWN HEALTH NOW ADMINISTERING COVID-19 VACCINES TO THOSE 16 AND OLDER AT NO CHARGE

RENO, Nev., April 01, 2021 (GLOBE NEWSWIRE) — Renown Health has been working with the Washoe County Health District, the state, and the CDC to distribute the limited supplies of COVID-19 vaccines. Renown has vaccinated over 48,000 people to date, which includes all of Tier 1A (Medical Staff members, Renown employees, students and volunteers) and eligible community members (those aged 65+ and those 45+ with an underlying health condition).

“Today, Renown is excited to announce that anyone aged 16+ is eligible to receive the COVID-19 vaccine at Renown’s COVID-19 Drive-Thru Vaccine site, at no cost to them. Over 7,500 vaccine appointments are now available for April,” said Tony Slonim, MD, DrPH, President and CEO of Renown Health. “Knowing we are closer to our goal that everyone who is interested in receiving the vaccine now has an opportunity to be vaccinated, gives me hope for the future. We are pleased to be part of the solution for our community and to make a genuine difference in the health and well-being of others.”

Vaccine appointments for 16+ will begin on Tuesday, April 6 at Renown’s Drive-Thru Vaccine site. The vaccine is offered at no charge. If appointments are filled, residents will be notified through their MyChart account when more appointments become available.


The vaccine clinic is operating by appointment only
. To be invited to make a vaccine appointment:

• Anyone aged 18 and older may register for a free Renown EPIC MyChart account. They do not need to be enrolled with a Renown provider to enroll. With a MyChart account, you will be able to login and schedule your 1st vaccine appointment. These vaccines require two doses. After the first dose of the vaccine is documented in your MyChart account, you will get a notice to schedule your 2nd dose.

• We have made special arrangements for minors ages 16 and 17. To make a vaccine appointment for those 16 or 17, please fill out this form, and a Renown representative will call them to arrange a vaccine appointment.

If issues arise obtaining an account or password, the MyChart service desk can be reached 24/7 at 775-982-2781. Please be patient, as they are experiencing heavy demand.

 “We thank the Washoe County Health District for their incredible partnership and collaboration, and are pleased to help meet the vaccination needs of our community. We have vaccinated more than 48,000 people with their first and second doses of the COVID-19 vaccine,” said Melodie Osborn, RN, Chief Nursing & Quality Officer for Health Services. “As we open vaccine appointments to all eligible groups, our goal is to continue providing an exceptional experience. We appreciate the public’s ongoing patience and support of this important work. This process will take time, and we must continue diligent mask wearing, physical distancing and other safety measures.”

Please see b-roll, photos and fly-over footage of our Drive-Thru COVID-19 Vaccination Clinic here.


Scheduling is still limited

Both the Pfizer and Moderna COVID-19 vaccines require two doses, the second administered three to four weeks after the first. Renown is working to be sure those who receive their first dose also obtain their second dose in a timely manner. Additionally, the FDA has only authorized the Pfizer vaccine for individuals ages 16-17.

We understand people may be on several waiting lists to receive the vaccine. We ask those who have the opportunity to get the vaccine through a community entity other than Renown, cancel their appointment as soon as possible to help ensure another interested individual is able to fill it. 


Why is Renown using MyChart?

Renown has been able to distribute and administer the COVID-19 vaccine to a record number of people in the shortest possible time. Much of this success is due to the use of EPIC MyChart, a convenient patient electronic medical record that allows people to schedule their appointments online, complete the consent form and have full documentation for the future. In addition, the information automatically posts to Web IZ, Nevada’s Statewide Immunization Information System.

Due to unprecedented demand, Renown is coordinating with local and state agencies to ensure every person has an opportunity to receive the vaccine over time. Signing up for a MyChart account is not a guarantee of an appointment.

For step-by-step instructions on how to schedule your COVID-19 vaccine appointment in MyChart, please visit our website. 

You are advised NOT to receive the vaccine if you:

  • Are ill at the time of vaccination (fever, shortness of breath, vomiting, diarrhea or acute illness).
  • Have been diagnosed with COVID-19 in the previous 14 days.
  • Have received any other vaccination in the last 14 days.
  • Have a history of significant allergic reaction to this vaccine or any of its ingredients.

Renown will provide additional updates on our website at covid.renown.org.

###

About Renown Health

Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.



Renown Health Public Relations
Renown Health
775-691-7308
[email protected]

Posted on

Energy Transfer and Centurion Pipeline to Provide Joint Tariff Crude Oil Service From Platteville and Cushing to Nederland

Energy Transfer and Centurion Pipeline to Provide Joint Tariff Crude Oil Service From Platteville and Cushing to Nederland

DALLAS & HOUSTON–(BUSINESS WIRE)–Energy Transfer LP (NYSE: ET) and Centurion Pipeline L.P. (“Centurion”) announced today that they will post a joint tariff for crude oil transportation service from ET’s terminals in Platteville, Colorado and Cushing, Oklahoma to ET’s Nederland, Texas terminal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210401005923/en/

The joint tariff service utilizes existing ET and Centurion pipeline assets that will be linked together via new connections in Oklahoma. The joint tariff service is expected to commence service by June 1, 2021. The joint tariff service may also be expanded to include an origin point of Guernsey, Wyoming. For parties interested in becoming a committed shipper, please contact Misbah Tukdi at [email protected] or Scott Hutson at [email protected].

About Energy Transfer LP

Energy Transfer LP (NYSE: ET) owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with a strategic footprint in all of the major domestic production basins. ET is a publicly traded limited partnership with core operations that include complementary natural gas midstream, intrastate and interstate transportation and storage assets; crude oil, natural gas liquids (NGL) and refined product transportation and terminalling assets; NGL fractionation; and various acquisition and marketing assets. ET, through its ownership of Energy Transfer Operating, L.P., also owns Lake Charles LNG Company, as well as the general partner interests, the incentive distribution rights and 28.5 million common units of Sunoco LP (NYSE: SUN), and the general partner interests and 46.1 million common units of USA Compression Partners, LP (NYSE: USAC). For more information, visit the Energy Transfer website at energytransfer.com.

About Centurion Pipeline L.P.

Centurion Pipeline L.P. is a crude oil pipeline operator that owns and operates approximately 3,000 miles of pipeline extending from southeast New Mexico across the Permian Basin of West Texas to delivery points at Midland, Texas, Cushing, Oklahoma, and Crane, Texas. With a significant crude oil storage facility in Midland, TX that has the capability to store approximately two million barrels of multiple qualities of crude oil, the company is well positioned to accommodate customer demand and provide connectivity to every long-haul pipeline from the Permian to the Texas Gulf Coast. Centurion is a wholly owned subsidiary of Lotus Midstream, LLC.

Energy Transfer Forward-Looking Statements

This news release may include certain statements concerning expectations for the future that are forward-looking statements as defined by federal law. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that are difficult to predict and many of which are beyond management’s control. An extensive list of factors that can affect future results are discussed in the Partnership’s Annual Report on Form 10-K and other documents filed from time to time with the Securities and Exchange Commission, including the Partnership’s Quarterly Report on Form 10-Q to be filed for the current period. In addition to the risks and uncertainties previously disclosed, the Partnership has also been, or may in the future be, impacted by new or heightened risks related to the COVID-19 pandemic, and we cannot predict the length and ultimate impact of those risks. The Partnership undertakes no obligation to update or revise any forward-looking statement to reflect new information or events.

Energy Transfer Contacts

Investor Relations:

Bill Baerg

Brent Ratliff

Lyndsay Hannah

214-981-0795

Media Relations:

Vicki Granado

214-840-5820

Centurion Contact

Media Contact:

Casey Nikoloric

303.507.0510 m

[email protected]

KEYWORDS: United States North America Colorado Oklahoma Texas

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on April 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee. The inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.

The inducement grants consisted of a non-statutory option to purchase 60,000 shares of the Company’s common stock, and two separate grants of 10,000 restricted stock units for shares of the Company’s common stock.

The stock option has an exercise price of $6.49 per share, equal to the closing price of Iveric Bio’s common stock on April 1, 2021. The stock option has a ten-year term and vests over four years, with 25% of the shares underlying the option vesting on April 1, 2022 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The first grant of 10,000 restricted stock units for shares of the Company’s common stock vests with respect to 25% of the shares underlying the grant on each of April 1, 2022, April 1, 2023, April 1, 2024 and April 1, 2025. The second grant of 10,000 restricted stock units for shares of the Company’s common stock vests with respect to 100% of the shares underlying the grant on April 1, 2022. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

ISEE-G

Investors / Media:

Iveric Bio

Kathy Galante, 212-845-8231

Vice President, Investor Relations and Corporate Communications

[email protected]

Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes

HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States.

The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.

“As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,” said Charles Caso, Vice President of Sales and Marketing for Chembio. “Based on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.”

About Chembio Diagnostics

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Contact:  
Brian Johnston
Gilmartin Group
631-807-1986
[email protected]